Magazine Article | October 3, 2022

Where Bioprocessing Outsourcers Stand On Capacity Concerns

Source: Life Science Leader

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

Roughly four years ago, ISR added several capacity questions to our syndicated research on outsourced biologic drug substance manufacturing to understand how sponsors perceive available bioprocessing capacity. Our goal is to better understand if, and when, a capacity crunch may be coming. The first set of results from Q4 2018 relayed that roughly one-quarter of respondents’ companies (23%) were concerned there would not be sufficient available bioprocessing capacity to meet their organizations’ outsourced manufacturing needs. Forty percent of respondents in 2018 said No, their companies were not concerned about available bioprocessing capacity, and 37% said Maybe.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader